Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry StudyTessa Straatmijer, Joep Grootjans, Gerard Dijkstra et al.|Clinical Gastroenterology and Hepatology|2022Cited by 51
Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC RegistryTessa Straatmijer, Marjolijn Duijvestein, Fiona D M van Schaik et al.|Alimentary Pharmacology & Therapeutics|2022Cited by 28
DOP75 Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry studyTessa Straatmijer, Marjolijn Duijvestein, Marijn C. Visschedijk et al.|Journal of Crohn s and Colitis|2022Cited by 0
Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis RegistryLoriane Marina Michèle Verleye, Tessa Straatmijer, Marieke J Pierik et al.|Inflammatory Bowel Diseases|2026Cited by 0